RecruitingNCT05231135

A Registry Study on HIV-related Lymphoma

Characteristics, Treatment and Outcomes of HIV-infected Patients With Malignant Lymphoma: A Registry Study of the European Hematology Association (EHA) Lymphoma Group

Sponsor

Rotkreuzklinikum München gGmbH

Enrollment

300 participants

Start Date

Aug 25, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma
HIV-infection at time of lymphoma diagnosis
Lymphoma diagnosis since 01.01.2010
Adult patients ≥ 18 years
Written informed consent

Exclusion Criteria2

HIV-diagnosis \> 3 months after the diagnosis of malignant lymphoma
Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)

Locations(6)

Red Cross Hospital Munich

Munich, Select One Option, Germany

University Hospital Cologne

Cologne, Germany

Amsterdam University Medical Centers

Amsterdam, Netherlands

Hospital de la Santa Creu i Sant Pau

Barcelona, Spain

Hospital Universitario de Salamanca

Salamanca, Spain

University Hospital of Wales

Cardiff, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05231135